Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Interventions: DRUG: Doxorubicin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Cyclophosphamide
Sponsor: Barretos Cancer Hospital